Texas AG Launches Probe Into Companies Promoting Drugs As Puberty Blockers Without FDA Approval

Image by Sharon McCutcheon from Pixabay

There is no doubt that the last year of American politics have seen some of the most hotly contested social and political issues in our culture come to a head, particularly when it comes to gender identity, accommodations for transgender individuals, and how children who identify as transgender are treated.

On the one hand, you have schools actively working to undermine parental authority by permitting or even encouraging children to pursue alternative gender identities without their parents’ consent or even knowledge, in some cases.

On the other hand, states like Arkansas and Tennessee have gone as far as to ban life-altering treatments for children such as hormone blockers or irreversible gender transition surgeries.

Now, Texas Attorney General Ken Paxton has announced a probe into two companies, Endo Pharmaceuticals and AbbVie Inc, that are promoting the use of common drugs as puberty blockers when the medication has not been approved by the Food and Drug Administration for such purposes.

Paxton’s office is investigating whether the pharmaceutical companies have violated the Texas Deceptive Trade Practices Act.

“These pharmaceutical companies allegedly advertised and promoted hormone (puberty) blockers for unapproved uses without disclosing the potential risks associated with these drugs to children and their parents,” he said in a statement.

“Medications Supprelin LA and Lupron Depot are approved to treat children with Central Precocious Property (CPP), when the puberty process begins prematurely. And Vantas, along with other forms of Lupron, has been prescribed for palliative treatment of prostate cancer. These drugs are now being used to treat gender dysphoria even though they are not approved for such use by the Food and Drug Administration (FDA).”

“The manufacture, sale, prescription, and use of puberty blockers on young teens and minors is dangerous and reckless,” Paxton said. “These drugs were approved for very different purposes and can have detrimental and even irreversible side effects.”

The Christian Post notes that, earlier this year, a hospital in Sweden that had been one of the premier medical facilities in the world for transgender treatments for children announced it would no longer be using puberty blockers in children under the age of 16 over safety concerns.

If you appreciate the work we are doing for faith, family, and freedom, please consider a small donation to help us continue. Thank you so much!